Esperion recalls NEXLIZET (bempedoic acid and ezetimibe) tablets, 180 mg/10 mg, 30-count bottle, Rx only, Manufactured for: Esperion Ther
Recalled April 24, 2024 · FDA recall D-0441-2024 · Esperion
Hazard
Failed dissolution specifications: out-of-specification bempedoic acid dissolution at the 0-month timepoint. · FDA Class III
Units
3,480 30-count bottles
Sold at
Nationwide in the USA
Description
Failed dissolution specifications: out-of-specification bempedoic acid dissolution at the 0-month timepoint.
Product
NEXLIZET (bempedoic acid and ezetimibe) tablets, 180 mg/10 mg, 30-count bottle, Rx only, Manufactured for: Esperion Therapeutics, Ann Arbor, MI 48108, NDC 72426-818-03
Manufacturer(s)
Esperion
Source: U.S. Food and Drug Administration. Official recall notice on fda.gov →